Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

There was higher frequency of hypophysitis, and adrenal insufficiency in late-phase trials but these differences did not reach statistical significance (i.e., 0.18% vs. 0.24% 0% vs. 0.12% in phase 1 and late-phase trials, respectively).

also in 111,027 other papers